FY2021 EPS Estimates for Exelixis, Inc. (NASDAQ:EXEL) Lifted by Analyst

Exelixis, Inc. (NASDAQ:EXEL) – William Blair boosted their FY2021 earnings estimates for shares of Exelixis in a report released on Tuesday, January 11th. William Blair analyst A. Hsieh now expects that the biotechnology company will earn $0.51 per share for the year, up from their prior estimate of $0.43. William Blair also issued estimates for Exelixis’ FY2022 earnings at $0.94 EPS and FY2023 earnings at $1.35 EPS.

Several other equities analysts have also issued reports on EXEL. Oppenheimer decreased their price target on shares of Exelixis from $30.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, November 2nd. HC Wainwright decreased their price target on shares of Exelixis from $65.00 to $52.00 and set a “buy” rating for the company in a report on Wednesday, November 3rd. Zacks Investment Research lowered shares of Exelixis from a “buy” rating to a “sell” rating and set a $23.00 price target for the company. in a report on Monday, November 8th. Piper Sandler assumed coverage on shares of Exelixis in a report on Friday, November 19th. They issued an “overweight” rating and a $34.00 price target for the company. Finally, Royal Bank of Canada decreased their price target on shares of Exelixis from $32.00 to $31.00 and set an “outperform” rating for the company in a report on Wednesday, November 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of “Buy” and an average target price of $32.18.

Shares of Exelixis stock opened at $18.12 on Thursday. The firm has a fifty day moving average of $17.86 and a two-hundred day moving average of $18.80. The stock has a market capitalization of $5.73 billion, a price-to-earnings ratio of 35.53, a PEG ratio of 0.57 and a beta of 0.89. Exelixis has a 52 week low of $15.50 and a 52 week high of $25.77.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, November 2nd. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.07). The business had revenue of $328.42 million for the quarter, compared to the consensus estimate of $366.34 million. Exelixis had a net margin of 13.10% and a return on equity of 8.27%. During the same quarter in the previous year, the firm posted ($0.10) EPS.

In other Exelixis news, EVP Peter Lamb sold 47,500 shares of the stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $18.09, for a total value of $859,275.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jeffrey Hessekiel sold 5,117 shares of the stock in a transaction dated Monday, November 1st. The shares were sold at an average price of $22.03, for a total transaction of $112,727.51. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 137,353 shares of company stock worth $2,450,124. 3.30% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in EXEL. FMR LLC grew its position in shares of Exelixis by 32.6% during the 2nd quarter. FMR LLC now owns 20,101,588 shares of the biotechnology company’s stock worth $366,251,000 after purchasing an additional 4,943,980 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Exelixis by 24.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,133,144 shares of the biotechnology company’s stock worth $257,507,000 after purchasing an additional 2,770,928 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its position in shares of Exelixis by 1,351.2% during the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 2,732,065 shares of the biotechnology company’s stock worth $57,756,000 after purchasing an additional 2,543,798 shares in the last quarter. Janus Henderson Group PLC acquired a new position in shares of Exelixis during the 3rd quarter worth approximately $38,838,000. Finally, Polar Capital Holdings Plc grew its position in shares of Exelixis by 42.1% during the 3rd quarter. Polar Capital Holdings Plc now owns 4,071,968 shares of the biotechnology company’s stock worth $86,081,000 after purchasing an additional 1,205,726 shares in the last quarter. 82.96% of the stock is currently owned by hedge funds and other institutional investors.

About Exelixis

Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.

Further Reading: Shanghai Stock Exchange Composite Index

Earnings History and Estimates for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.